Good MorningEquity markets started the weak on stable footing but could not post substantial gains on Monday. The move is partly due to easing fear of a banking crisis compounded by uncertainty about the PCE data on Friday. The analysts expect core PCE to moderate to 0.4% month-to-month but remain hot at 4.7% YOY. At this level, the FOMC may need to hike interest rates beyond the recently intended target, and there is a risk it will come in hotter than expected.
With only 2 weeks until the start of the Q2 peak earnings reporting cycle, the market is bracing for what could be a very bad season. The consensus target for Q1 earnings is below -6.0% and it could be worse by the end of the season. The details that will more the market are the guidance and outlook for the 2nd half of the year, if those take another hit this market will move one step closer to another major sell-off. Featured: 5 Stocks Poised to Soar Under Trump's Presidency (Ad) 
|
Stocks | | |
Analysts can be a powerful force in the market. If there are enough of them covering a stock, when their sentiment changes, it will move the stock price. Marketbeat.com’s analyst tracking tools will show 3 names that reported solid results for CQ4, gave positive guidance, and earned a round ... Read the Full Story |
|
From Our PartnersWhat If Washington Declared That:
YOUR Money ISN'T Actually Yours?
Sounds insane, but that's exactly what the Department of Justice just admitted in court—claiming cash isn't legally your property.
What does that mean? It means Washington thinks they can seize, freeze, or drain your accounts—whenever they want. | | | Get your free guide now by clicking here >> |
|
Stocks | | |
While the enterprise software makers are in the doldrums, and the financial sector tries to recover from a battering, a few specialty software firms, including Intapp Inc. (NASDAQ: INTA), Vertex Inc. (NASDAQ: VERX), and GuidewIre Software Inc. (NYSE: GWRE) are headed toward greater profitability, ... Read the Full Story |
|
Stocks | | |
For the last year, investors have heard the advice that “cash is king.” Cash is also important when it comes to the companies you choose to invest in. And while this is a difficult market, there are still opportunities for buy-and-hold investors with a suitable time horizon. And the th... Read the Full Story |
|
From Our Partners2025 is off to a turbulent start—markets are swinging wildly, inflation pressures remain high, and recession fears are creeping back into headlines.
But even in uncertain times, innovation doesn’t slow down.
In fact, artificial intelligence (AI) is accelerating faster than ever—creating new profit opportunities while the broader market struggles.
Our latest research reveals two AI stocks trading under $15 that could thrive even as volatility grows. These under-the-radar companies are positioned to ride the next wave of AI-driven demand—and they’re still flying below most investors’ radar. | | | 👉[Click here to access your FREE AI stocks report now.] |
|
Markets | | | Credit Suisse shares plunged Monday after Swiss authorities cut a deal with its bigger rival UBS to acquire the troubled bank at a marked-down price. But European bank stocks and the wider market gained as investors watch whether moves to shore up banks will stem further upheaval in the global finan... Read the Full Story |
|
Markets | | | In a bid to ease turmoil in the world financial system, Swiss authorities engineered a plan for the UBS bank to acquire its troubled smaller rival Credit Suisse at a marked-down price.It's another urgent attempt to fight fears that have put the financial world on edge 15 years after the failure of U... Read the Full Story |
|
|
Markets | | |
Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) is positioned to make a new run at the 52-week high of $325.19 as the stock is confirming a cup base pattern. The biotechnology company’s stock is up 7.3% in the last month and just announced some news that could send the stock much higher.
... Read the Full Story |
|
Markets | | | Working against the clock to stop a developing banking crisis, Treasury Secretary Janet Yellen had until sunset on Sunday, March 12, to come up with a plan to calm the U.S. economy. She quickly turned to someone who had been through the fire before, and on a much larger scale: Hank Paulson. Paulson,... Read the Full Story |
|
Markets | | |
Shares of Sanofi (NASDAQ: SNY) were up 10.20% the week ended March 24, while Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) finished with a gain of 9.68%, following promising news about the companies’ jointly developed medication Dupixent.
In Phase 3 clinical trials, Dupixent reduced severe ... Read the Full Story |
|
Markets | | | While Wall Street works to contain the biggest American bank failure since the 2008 financial meltdown, founders of startups who are people of color worry it could become even harder to secure financial support Read the Full Story |
|
Stocks | | | Two large banks that cater to the tech industry have collapsed after a bank run, government agencies are taking emergency measures to backstop the financial system, and President Joe Biden is reassuring Americans that the money they have in banks is safe Read the Full Story |
|
Tuesday's Early Bird Stock Of The Day Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts. | | View Today's Stock Pick |
|
